Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · IEX Real-Time Price · USD
0.490
-0.020 (-3.86%)
At close: Apr 19, 2024, 4:00 PM
0.500
+0.010 (1.98%)
After-hours: Apr 19, 2024, 7:54 PM EDT
Kiora Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for KPRX stock have an average target of 2.00, which predicts an increase of 307.91% from the current stock price of 0.49.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KPRX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +307.91% | Mar 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3.5 → $2 | Strong Buy | Maintains | $3.5 → $2 | +307.91% | Feb 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3.5 | Strong Buy | Reiterates | $3.5 | +613.85% | Nov 13, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2 → $3.5 | Strong Buy | Maintains | $2 → $3.5 | +613.85% | Nov 6, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2 | Strong Buy | Reiterates | $2 | +307.91% | Aug 24, 2023 |
Financial Forecast
Revenue This Year
10.46M
Revenue Next Year
1.53M
from 10.46M
Decreased by -85.37%
EPS This Year
-0.07
from -2.69
EPS Next Year
-0.29
from -0.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 21.5M | 3.2M | n/a | 30.2M | 94.5M |
| Avg | 10.5M | 1.5M | n/a | 24.3M | 69.1M |
| Low | n/a | n/a | n/a | 18.6M | 44.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | -69.9% | - | - | 288.0% |
| Avg | - | -85.4% | - | - | 184.0% |
| Low | - | - | - | - | 83.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.18 | -0.21 | -0.16 | 0.05 | 1.00 |
| Avg | -0.07 | -0.29 | -0.24 | 0.05 | 0.97 |
| Low | -0.31 | -0.35 | -0.32 | 0.05 | 0.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 1,855.9% |
| Avg | - | - | - | - | 1,800.0% |
| Low | - | - | - | - | 1,725.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.